Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Richard Furie's publication output changed over time?
ScholarIQpublication output · 2003–2023
Output grew0% over the shown period — from 1 works in 2003 to 1 in 2023.
1
1
1
1
1
2
1
2
1
1
2003200620092011201220162018201920202023
What are the most-cited papers on Richard Furie?
ScholarIQmost cited works
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie, Michelle Petri, Omid Zamani, Ricard Cervera, Daniel J. Wallace, Dana Tegzová, Jorge Sánchez‐Guerrero, Andreas Schwarting, Joan T. Merrill, Winn Chatham, William Stohl, Ellen M. Ginzler, Douglas R. Hough, Z. John Zhong, William W. Freimuth, Ronald van Vollenhoven, BLISS-76 Study Group
S132787887. 20111,675 CitationsOPEN ACCESS
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Stanley Cohen, Paul Emery, Maria Greenwald, Maxime Dougados, Richard Furie, Mark C. Genovese, Edward Keystone, J. Loveless, Gerd‐Rüdiger Burmester, Matthew Cravets, E. Hessey, T Shaw, Mark C. Totoritis
S132787887. 20061,643 Citations
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
Brad H. Rovin, Richard Furie, Kevin Latinis, R. John Looney, Fernando C. Fervenza, Jorge Sánchez‐Guerrero, Romeo Maciuca, David Zhang, Jay Garg, Paul Brunetta, Gerald B. Appel, LUNAR Investigator Group
S132787887. 20121,454 Citations
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand, Richard Furie, Yoshiya Tanaka, Ian N Bruce, Anca Askanase, Christophe Richez, Sang‐Cheol Bae, Philip Z. Brohawn, Lilia Pineda, Anna Berglind, Raj Tummala
New England Journal of Medicine. 20191,357 CitationsOPEN ACCESS
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie, Brad H. Rovin, Frédéric Houssiau, Ana Malvar, Y K Onno Teng, Gabriel Contreras, Zahir Amoura, Xueqing Yu, Chi-Chiu Mok, Mittermayer B. Santiago, Amit Saxena, Yulia Green, Beulah Ji, C. Kleoudis, Susan W. Burriss, Carly Barnett, David A. Roth
New England Journal of Medicine. 20201,005 CitationsOPEN ACCESS
Related on ScholarIQ
Northwell Health
Institution
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Paper
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Paper
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
Paper
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Paper
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Paper